Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Boehringer Ingelheim
Merck
Harvard Business School
McKinsey
QuintilesIMS

Generated: September 22, 2019

DrugPatentWatch Database Preview

Patent: 4,686,104

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 4,686,104
Title: Methods of treating bone disorders
Abstract:Metal-containing compounds have been found to decrease calcium resorption from bone. These compounds, when administered to patients who are suffering from diseases characterized by accelerated bone resorption, impede the flow of bone calcium into the blood and increase the calcium content of bone tissue.
Inventor(s): Bockman; Richard S. (New York, NY), Warrell, Jr.; Raymond P. (New York, NY)
Assignee: Sloan-Kettering Institute for Cancer Research (New York, NY)
Application Number:06/853,144
Patent Claims:see list of patent claims

Details for Patent 4,686,104

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   Try a Free Trial Sloan-Kettering Institute for Cancer Research (New York, NY) 2036-04-30 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   Try a Free Trial Sloan-Kettering Institute for Cancer Research (New York, NY) 2036-04-30 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   Try a Free Trial Sloan-Kettering Institute for Cancer Research (New York, NY) 2036-04-30 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23   Try a Free Trial Sloan-Kettering Institute for Cancer Research (New York, NY) 2036-04-30 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
QuintilesIMS
Cipla
US Army
UBS
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.